Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.

An earnings report is a powerful tool that allows you to peek under the hood of your favorite companies to see whether they're investment-worthy. Read on to learn more.

H.B. Fuller Company (NYSE: FUL) today reported financial results for its fourth quarter and fiscal year that ended November 29, 2025.

Concentrix (CNXC) shifts to GenAI/SaaS beyond call centers; strong free cash flow, buybacks and dividend support value under ...

Groupon earnings show improving merchant economics and 7% topline growth, but high capital costs and Italy tax settlements ...

Clover delivers market-leading Medicare Advantage growth, establishing a strong path to achieve its first-ever full year GAAP Net Income ...

Q4 2025 Earnings Call Transcript January 13, 2026 Concentrix Corporation beats earnings expectations. Reported EPS is $2.95, ...

For the first quarter of 2026, the company's preliminary outlook reflects revenue of at least $240 million, and sequential improvement in gross margin, compared to the fourth quarter. Ichor will ...

Completed business combination with Husky Technologies creating a $7.4 billion best-in-class, diversified compounder; Rebrands corporate entity to GPGI, Inc. (“Great Positions i ...

Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership ...

Management to participate in fireside chat and one-on-one meetings at 28th Annual Needham Growth Conference January 14, ...

Discover the hidden details in financial footnotes essential for interpreting income statements, balance sheets, and cash ...